PDI204

PDI204 is an investigational monoclonal antibody developed for the **treatment and prevention of COVID-19**. It belongs to the VH1-58 stereotypic class of antibodies, which are recognized for maintaining broad recognition and potent neutralization across different SARS-CoV-2 variants of concern. Structural analysis reveals that PDI204 binds to the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein, with a binding footprint that partially overlaps the ACE2 interaction site but does not directly contact key side chains that are often mutated in variants, which contributes to its broad activity[1][7][9]. The drug was initially developed at the University of Melbourne and has entered **Phase 1 clinical trials** to assess its safety, tolerability, and pharmacokinetics in healthy volunteers[5][7][9]. The intended route of administration and dosing are under clinical evaluation.